Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease

Next Previous
Trial Profile

A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 26 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sabirnetug (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Dementia
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTITUDE-AD
  • Sponsors Acumen Pharmaceuticals

Most Recent Events

  • 17 Mar 2026 According to an Acumen Pharmaceuticals media release, company presents findings at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD), taking place March 17-21, in Copenhagen and online.
  • 02 Dec 2025 According to an Acumen Pharmaceuticals media release, the study tracked 2,362 participants screened across 76 sites, with 542 ultimately enrolled. Out of the 6 recruitment methods used, site databases and physician referrals were most effective for recruiting due to established relationships and pre-screened eligibility.
  • 18 Nov 2025 According to an Acumen Pharmaceuticals media release, the company will present new findings and recruitment strategies for this trial 18th Annual Clinical Trials on Alzheimers Disease (CTAD) on December 1-4, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top